452 related articles for article (PubMed ID: 14608758)
1. [Use of an implantable defibrillator for the prevention of sudden death in hypertrophic cardiomyopathy].
Hentati M; Ben Ameur I; Kechida Z; Charfeddine H; Hached L; Grati Z; Kammoun S
Tunis Med; 2003; 81 Suppl 8():675-9. PubMed ID: 14608758
[TBL] [Abstract][Full Text] [Related]
2. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
[TBL] [Abstract][Full Text] [Related]
3. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
5. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.
Cotiga D; Ehlert F; Sherrid M
Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():55-60. PubMed ID: 17162272
[TBL] [Abstract][Full Text] [Related]
6. Sudden death and hypertrophic cardiomyopathy: a review.
Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R
J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
9. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator.
Maron BJ
Eur Heart J; 2000 Dec; 21(24):1979-83. PubMed ID: 11102243
[No Abstract] [Full Text] [Related]
10. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P
J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
[TBL] [Abstract][Full Text] [Related]
11. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
[TBL] [Abstract][Full Text] [Related]
12. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
[TBL] [Abstract][Full Text] [Related]
13. [Massive myocardial hypertrophy in hypertrophic cardiomyopathy: a risk factor for sudden death and high defibrillation threshold during cardioverter-defibrillator implantation].
Jastrzebski M; Czarnecka D; Bacior B; Petkow-Dimitrow P; Wilczek R; Kawecka-Jaszcz K
Kardiol Pol; 2005 Aug; 63(2):191-5; discussion 196. PubMed ID: 16136416
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy].
Maron BJ
Rev Esp Cardiol; 2006 Jun; 59(6):527-30. PubMed ID: 16790193
[No Abstract] [Full Text] [Related]
15. [Interventional treatment in hypertrophic cardiomyopathy].
Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
[TBL] [Abstract][Full Text] [Related]
16. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of sudden death in hypertrophic cardiomyopathy (HCM ): implanted defibrillators in HCM].
Maron BJ; Spirito P
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):297-302. PubMed ID: 19791462
[TBL] [Abstract][Full Text] [Related]
18. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death.
Ostman-Smith I
Fundam Clin Pharmacol; 2010 Oct; 24(5):637-52. PubMed ID: 20727015
[TBL] [Abstract][Full Text] [Related]
20. [Hypertrophic cardiomyopathy with two episodes of recuperated sudden death. Report of the first implantable defibrillator cardioverter inserted in Chile].
Zalaquett R; Fajuri A; Irarrázaval MJ; Neghme R; Vergara I; Sacco C; Dubernet J; Corbalán R
Rev Med Chil; 1994 Oct; 122(10):1171-7. PubMed ID: 7659885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
